Researchers isolated a molecule that may be under-produced in the guts of patients
Researchers at the Weizmann Institute of Science have shown in mice that intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. As reported today in Nature,progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted by these microbes. Preliminary results suggest that the findings on the regulatory function of the microbiome may be applicable to human patients with ALS.
“Our long-standing scientific and medical goal is to elucidate the impact of the microbiome on human health and disease, with the brain being a fascinating new frontier,” says Prof. Eran Elinav of the Immunology Department. His team performed the study together with that of Prof. Eran Segal of the Computer Science and Applied Mathematics Department. Segal elaborates: “Given increasing evidence that microbiome affects brain function and disease, we wanted to study its potential role in ALS.” The study was led by postdoctoral fellows Drs. Eran Blacher and Stavros Bashiardes, and by staff scientist Dr. Hagit Shapiro, all in the Elinav lab. They collaborated with Dr. Daphna Rothschild, a postdoctoral fellow in Eran Segal’s lab, and Dr. Marc Gotkine, Head of the Motor Neuron Disease Clinic at Hadassah Medical Center, as well as with other scientists from Weizmann and elsewhere.
The scientists started out demonstrating in a series of experiments that the symptoms of an ALS-like disease in transgenic mice worsened after these mice were given broad-spectrum antibiotics to wipe out a substantial portion of their microbiome. In addition, the scientists found that growing these ALS-prone mice in germ-free conditions (in which, by definition, mice carry no microbiome of their own), is exceedingly difficult, as these mice had a hard time surviving in the sterile environment. Together, these results hinted at a potential link between alterations in the microbiome and accelerated disease progression in mice that were genetically susceptible to ALS.
Next, using advanced computational methods, the scientists characterized the composition and function of the microbiome in the ALS-prone mice, comparing them to regular mice. They identified 11 microbial strains that became altered in ALS-prone mice as the disease progressed or even before the mice developed overt ALS symptoms. When the scientists isolated these microbial strains and gave them one by one – in the form of probiotic-like supplements – to ALS-prone mice following antibiotic treatment, some of these strains had a clear negative impact on the ALS-like disease. But one strain, Akkermansia muciniphila, significantly slowed disease progression in the mice and prolonged their survival.
To reveal the mechanism by which Akkermansia may be producing its effect, the scientists examined thousands of small molecules secreted by the gut microbes. They zeroed in on one molecule called nicotinamide (NAM): Its levels in the blood and in the cerebrospinal fluid of ALS-prone mice were reduced following antibiotic treatment and increased after these mice were supplemented with Akkermansia, which was able to secrete this molecule. To confirm that NAM was indeed a microbiome-secreted molecule that could hinder the course of ALS, the scientists continuously infused the ALS-prone mice with NAM. The clinical condition of these mice improved significantly. A detailed study of gene expression in their brains suggested that NAM improved the functioning of their motor neurons.
One strain significantly slowed disease progression in the mice and prolonged their survival
Finally, the researchers examined the microbiome and metabolite profiles of 37 human ALS patients and compared them to those of family members sharing the same household. A detailed genomic analysis suggested that the gut microbiomes of ALS patients were distinct in composition and functional features from those of healthy controls. In particular, numerous microbial genes involved in the synthesis of NAM were significantly suppressed in ALS patients. An analysis of thousands of small molecules in the blood also revealed a distinct pattern in ALS patients as compared to controls. Here too, many of the intermediary molecules involved in the NAM synthesis were altered in the blood of ALS patients. When the researchers tested the levels of NAM itself, they found these to be significantly reduced in both the blood and the brain of 60 human ALS patients as compared to controls. Moreover, there was a correlation between reduced NAM levels and the degree of muscle weakness in the patients.
“These findings are only a first step towards achieving a comprehensive understanding of the potential impact of the microbiome on ALS,” Elinav says, “but they suggest that in the future, various means of altering the microbiome may be harnessed for developing new therapeutic options for ALS.”
Learn more: Gut Microbes May Affect the Course of ALS
The Latest on: Amyotrophic lateral sclerosis
via Google News
The Latest on: Amyotrophic lateral sclerosis
- "10 Days of Giving": Day 1 - Benjamin Merckon December 5, 2019 at 9:24 am
Benjamin Merck was originally chosen as a recipient for the 10 Days of Giving. Unfortunately, Ben passed away from Amyotrophic lateral sclerosis (ALS) on November 26, 2019 at the young age of 16. Ben ...
- 6 Charities and Non-Profits that We Loveon December 5, 2019 at 8:06 am
In honor of the holidays, we’re sharing some of our favorite charities and non-profits that we work with. Founded in 1982 to serve those with Amyotrophic Lateral Sclerosis, this chapter supports 31 ...
- Soleo Health Provides Mitsubishi Tanabe Pharma America With Real-World Data for ALS Patientson December 5, 2019 at 7:40 am
McKINNEY, Texas--(BUSINESS WIRE)--Soleo Health, an innovative national provider of complex specialty pharmacy and infusion services, announced today it provided real-world data to Mitsubishi Tanabe ...
- North Carolina Rep. Greg Murphy Touts ‘Critical’ US-Israel Relationshipon December 5, 2019 at 7:20 am
10 in the state’s 10th Congressional District to succeed the longtime Rep. Walter Jones Jr., who passed away earlier this year from amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease).
- Personalized Cell Therapy Market in-depth Analysis with Booming Trends and Forecast to 2027on December 5, 2019 at 12:04 am
Dec 05, 2019 (Heraldkeepers) -- Personalized cell therapy (PCT) involves injection of living cells into a patient's for the individualized treatment of various diseases such as cancer, autoimmune ...
- Darien native runs race to bring awareness to father’s rare diseaseon December 4, 2019 at 12:00 am
SPF also provides grants for PLS and HSP research, and raises money for those conditions through individual donations, such as Meg’s. Both conditions are related to amyotrophic lateral sclerosis (ALS) ...
- Mitsubishi Tanabe Pharma America To Spotlight Progress In ALS Research At 30th International Symposium On ALS/MNDon December 3, 2019 at 8:21 pm
Presentations Include U.S. Real-World Evidence on Edaravone for ALS JERSEY CITY, N.J., Dec. 2, 2019 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced six presentations on ...
- New clues about the origins of familial forms of amyotrophic lateral sclerosison December 2, 2019 at 12:05 pm
A team led by Brazilian researcher Elis Eleutherio, professor at the Federal University of Rio de Janeiro, in partnership with Tiago Outeiro, at University of Goettingen, Germany, made important ...
- Riluzole Oral Film Approved for Amyotrophic Lateral Sclerosison December 2, 2019 at 3:30 am
The oral film is applied to the top of the tongue where it adheres and dissolves. The Food and Drug Administration (FDA) has approved Exservan (riluzole oral film; Aquestive Therapeutics) for the ...
- Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis and its differential diagnosis valueon November 28, 2019 at 2:19 am
To explore differential diagnosis value of dissociated lower-limb muscle impairment, we performed a retrospective analysis of clinical and electrophysiological features in 141 lower-limb involved ALS ...
via Bing News